CLDX_OUT_1 [2025-04-29 09:18:24 -0400] 6050 Bytes | 1678 tokens | Cum: 1678 tkns (20.97% of 8k)
==========================================================================

Booyah, my friends! It's already 9:18 AM on Tue Apr 29, 2025, and I've got my eyes locked on Celldex Therapeutics (CLDX), pushing up to $21.36 from $19.57. Are we in for a serious bull run, or is this just hype? I've pulled the data—let's break it down!

--- COMPANY PROFILE ---
Company: Celldex Therapeutics (CLDX)
IPO: 1990-03-26 (35 Years Ago)
Market Cap: $1,040,566,237
Shares Outstanding: 66,379,999
Industry: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Exchange: XNAS
Description: Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.

Here’s a list of headlines for Celldex Therapeutics:

Apr-22-25 07:40AM - Celldex Therapeutics: Strong Pipeline But Uncertainties Remain
Mar-24-25 03:24PM - Cytokinetics (CYTK) Moves 5.4% Higher: Will This Strength Last?
Mar-20-25 11:44AM - Celldex a new overweight at Morgan Stanley on urticaria candidate
Mar-04-25 08:01AM - Celldex Therapeutics to Present at Upcoming Investor Conferences
Mar-03-25 08:01AM - Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025
Mar-01-25 12:45PM - Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025
Feb-27-25 05:30PM - Celldex Therapeutics (CLDX) Reports Q4 Loss, Lags Revenue Estimates
Feb-27-25 05:30PM 04:32PM - Celldex: Q4 Earnings Snapshot
Feb-27-25 05:30PM 04:01PM - Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
Dec-19-24 08:01AM - Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis
Nov-20-24 08:01AM - Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases
Nov-11-24 04:01PM - Celldex Therapeutics to Present at Upcoming Investor Conferences
Nov-06-24 05:30PM - Celldex Therapeutics (CLDX) Reports Q3 Loss, Tops Revenue Estimates
Nov-06-24 05:30PM 04:25PM - Celldex: Q3 Earnings Snapshot
Nov-06-24 05:30PM 04:01PM - Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Oct-29-24 12:05PM - Celldex selloff creates buying opportunity, says Guggenheim
Oct-26-24 05:43PM - Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria
Oct-25-24 08:01AM - Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024
Oct-23-24 08:39AM - Celldex Therapeutics (CLDX): A Top Small-Cap Growth Stock with Promising Clinical Results
Oct-15-24 06:10PM - Celldex Therapeutics, Inc. (CLDX): Hedge Funds Hidden Gem in Small-Cap Stocks
Sep-25-24 10:45AM - Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024
Sep-16-24 08:01AM - Celldex Announces Upcoming Late Breaking Oral Presentation of 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV Congress 2024

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2025-03-03T13:01:00Z - Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025
B2 - 2025-03-01T17:45:00Z - Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025
B3 - 2025-02-20T18:00:00Z - Chronic Spontaneous Urticaria Market to Register Incremental Growth During the Study Period (2020–2034) Owing to the Launch of Emerging Therapies | DelveInsight
B4 - 2024-12-19T13:01:00Z - Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis
B5 - 2024-11-04T18:00:00Z - Urticaria Clinical Trial Pipeline Accelerates: 20+ Leading Companies Pioneering New Treatments | DelveInsight
B6 - 2024-10-26T21:43:00Z - Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for Celldex Therapeutics (CLDX).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

CLDX_OUT_3 [2025-04-29 09:18:25 -0400] 968 Bytes | 258 tokens | Cum: 1938 tkns (24.22% of 8k)
==========================================================================

Showing B2 (chunk 1 of 1): B2:
**Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/03/01/3035114/24180/en/Celldex-Therapeutics-Presents-Positive-Results-from-Barzolvolimab-Phase-2-Studies-in-Patients-with-Chronic-Urticaria-Demonstrating-Improved-Disease-Control-and-Quality-of-Life-at-A.htmlCelldex Therapeutics announced positive data from Phase 2 studies of its drug barzolvolimab in patients with chronic urticaria, demonstrating improved disease control and quality of life.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CLDX_OUT_5 [2025-04-29 09:18:26 -0400] 1013 Bytes | 301 tokens | Cum: 2241 tkns (28.01% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-28T13:00:46Z - Analyst Expectations For Celldex Therapeutics's Future - Celldex Therapeutics (NASDAQ:CLDX)...
A2 - 2025-04-28T12:04:26Z - This Kohl's Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday - Celld...
A3 - 2025-04-25T07:35:01Z - Renaissance Technologies LLC Makes New $3.45 Million Investment in Celldex Therapeutics, Inc. (NASDA...
A4 - 2025-04-24T11:35:56Z - Silverarc Capital Management LLC Acquires 119,560 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)...
A5 - 2025-04-24T11:09:03Z - Eversept Partners LP Increases Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX)...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

CLDX_OUT_7 [2025-04-29 09:18:27 -0400] 1181 Bytes | 357 tokens | Cum: 2600 tkns (32.50% of 8k)
==========================================================================

Showing A1 (chunk 1 of 8): A1:
**Analyst Expectations For Celldex Therapeutics's Future - Celldex Therapeutics (NASDAQ:CLDX)**Date: 2025-04-28Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/insights/analyst-ratings/25/04/45037935/analyst-expectations-for-celldex-therapeuticss-futureAcross the recent three months, 7 analysts have shared their insights on Celldex Therapeutics CLDX, expressing a variety of opinions spanning from bullish to bearish.

The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 2 1 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 2 1 1 0 0 3M Ago 1 1 0 0 0

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $59.5

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CLDX_OUT_9 [2025-04-29 09:18:28 -0400] 1181 Bytes | 294 tokens | Cum: 2896 tkns (36.20% of 8k)
==========================================================================

Showing A1 (chunk 2 of 8): 7, with a high estimate of $80.00 and a low estimate of $36.00. Highlighting a 11.42% decrease, the current average has fallen from the previous average price target of $67.25.

Analyzing Analyst Ratings: A Detailed Breakdown

In examining recent analyst actions, we gain insights into how financial experts perceive Celldex Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

| Analyst | Analyst Firm | Action Taken | Rating |Current Price Target| Prior Price Target | |--------------------|--------------------|---------------|---------------|--------------------|--------------------| |Edward Nash |Canaccord Genuity |Announces |Buy | $64.00|- | |Judah Frommer |Morgan Stanley |Announces |Overweight | $46.00|- | |Richard Law |Goldman Sachs |Lowers |Neutral | $36.00|$42.00 | |Joseph Pantginis |HC Wainwright & Co. |M

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CLDX_OUT_11 [2025-04-29 09:18:29 -0400] 1181 Bytes | 298 tokens | Cum: 3196 tkns (39.95% of 8k)
==========================================================================

Showing A1 (chunk 3 of 8): aintains |Buy | $80.00|$80.00 | |Joseph Pantginis |HC Wainwright & Co. |Maintains |Buy | $80.00|$80.00 | |Trung Huynh |UBS |Announces |Buy | $44.00|- | |Kristen Kluska |Cantor Fitzgerald |Maintains |Overweight | $67.00|$67.00 |

Key Insights: Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Celldex Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company. Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Celldex Therapeutics compared to the broader market. Price Targets: Gaining insights, analysts pro

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CLDX_OUT_13 [2025-04-29 09:18:29 -0400] 1181 Bytes | 256 tokens | Cum: 3454 tkns (43.18% of 8k)
==========================================================================

Showing A1 (chunk 4 of 8): vide estimates for the future value of Celldex Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.

Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Celldex Therapeutics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.

Stay up to date on Celldex Therapeutics analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Unveiling the Story Behind Celldex Therapeutics

Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cance

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CLDX_OUT_15 [2025-04-29 09:18:30 -0400] 1181 Bytes | 262 tokens | Cum: 3718 tkns (46.48% of 8k)
==========================================================================

Showing A1 (chunk 5 of 8): r, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.

Celldex Therapeutics's Economic Impact: An Analysis

Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.

Revenue Growth: Celldex Therapeutics's revenue growth over a period of 3M has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -71.56%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.

Net Margin: The company's net margin is a

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CLDX_OUT_17 [2025-04-29 09:18:31 -0400] 1181 Bytes | 263 tokens | Cum: 3983 tkns (49.79% of 8k)
==========================================================================

Showing A1 (chunk 6 of 8): standout performer, exceeding industry averages. With an impressive net margin of -4007.83%, the company showcases strong profitability and effective cost control.

Return on Equity (ROE): Celldex Therapeutics's ROE excels beyond industry benchmarks, reaching -6.14%. This signifies robust financial management and efficient use of shareholder equity capital.

Return on Assets (ROA): Celldex Therapeutics's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -5.83%, the company may face hurdles in achieving optimal financial returns.

Debt Management: Celldex Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.01.

How Are Analyst Ratings Determined?

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CLDX_OUT_19 [2025-04-29 09:18:32 -0400] 1181 Bytes | 259 tokens | Cum: 4244 tkns (53.05% of 8k)
==========================================================================

Showing A1 (chunk 7 of 8): Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.

Breaking: Wall Street's Next Big Mover

Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

CLDXCelldex Therapeutics Inc$19.861.48%Stock

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CLDX_OUT_21 [2025-04-29 09:18:32 -0400] 534 Bytes | 146 tokens | Cum: 4392 tkns (54.90% of 8k)
==========================================================================

Showing A1 (chunk 8 of 8): Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock - anytime.

Reveal Full ScoreEdge RankingsMomentum14.77Growth-Quality-Value3.41Price TrendShortMediumLongOverviewMarket News and Data brought to you by Benzinga APIs

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CLDX_OUT_23 [2025-04-29 09:18:33 -0400] 1056 Bytes | 289 tokens | Cum: 4683 tkns (58.54% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-02-27 10-K Item 7. MGT DISC & ANALYSIS OF FIN COND & RESULTS OF OPER

OVERVIEW

We are a biopharmaceutical company dedicated to exploring the science of mast cell biology and developing therapeutic antibodies which have the ability to engage the human i...

S2 - 2025-02-27 8-K Item 2.02. Results of Oper and Fin Cond.

On February 27, 2025, Celldex Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the fourth quarter and year ended 2024. The full text of the press release is furnished as Exhi...

S3 - 2024-11-06 10-Q PART I FIN INFO

Item 1. Unaudited Fin Stmnts

CELLDEX THERAPEUTICS, INC.

COND CONS BAL SHEETS

(Unaudited)

(In thousands, except share and per share amounts)

September 30,

December 31,

Assets

Curr assets:

Cash and cash ...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

CLDX_OUT_25 [2025-04-29 09:18:34 -0400] 1181 Bytes | 255 tokens | Cum: 4940 tkns (61.75% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
Item 7. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

OVERVIEW

We are a biopharmaceutical company dedicated to exploring the science of mast cell biology and developing therapeutic antibodies which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Our drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate.

We are focusing our efforts and resources on the continued research and development of

##TABLE_START Barzolvolimab (also referred to as CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is currently being studied across mul

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CLDX_OUT_27 [2025-04-29 09:18:37 -0400] 1181 Bytes | 282 tokens | Cum: 5224 tkns (65.30% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6): tiple mast cell driven diseases including ##TABLE_END

##TABLE_START - Chronic Urticarias: We initiated Phase 3 studies in chronic spontaneous urticaria (CSU) in July 2024. In November 2023, we announced that our Phase 2 study in CSU achieved the primary efficacy endpoint (statistically significant mean change from baseline to week 12 of urticaria activity score compared to placebo) and was well tolerated. Patients on study continued to receive barzolvolimab and, in September 2024, we reported data from 52 weeks of treatmentdemonstrating sustained and deepening disease efficacy and a well tolerated long term safety profile. In July 2024, we announced that our Phase 2 study in chronic inducible urticaria (CIndU) achieved the primary efficacy endpoint, (statistically significant difference between the percent of patients with a negative provocation test compared to placebo at week 12) and

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CLDX_OUT_29 [2025-04-29 09:18:38 -0400] 1181 Bytes | 299 tokens | Cum: 5525 tkns (69.06% of 8k)
==========================================================================

Showing S1 (chunk 3 of 6): was well tolerated. 12 week data from the CIndU study were presented in October of 2024 and all secondary endpoints across the study were also met and were highly statistically significant and clinically meaningful. Patients on study continued to receive barzolvolimab for 20 weeks of treatment; ##TABLE_END##TABLE_START - Prurigo Nodularis (PN): In April 2024, we initiated a Phase 2 study in PN and enrollment is ongoing; positive data from a Phase 1b study in PN was reported in November 2023; ##TABLE_END##TABLE_START - Eosinophilic Esophagitis (EoE): A Phase 2 study in EoE was initiated in June 2023 and is fully accrued; and ##TABLE_END##TABLE_START - Atopic Dermatitis (AD): A Phase 2 study in AD was initiated in December 2024 and enrollment is ongoing. ##TABLE_END

##TABLE_START Our next generation bispecific antibody platform to support pipeline expansion with additional candidates fo

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CLDX_OUT_31 [2025-04-29 09:18:39 -0400] 1181 Bytes | 268 tokens | Cum: 5795 tkns (72.44% of 8k)
==========================================================================

Showing S1 (chunk 4 of 6): r inflammatory diseases. Targets are being selected based on new science as well as their compatibility to be used in bispecific antibody formats with our existing antibody programs. Development is focused on emerging, important pathways controlling inflammatory diseases. ##TABLE_END

##TABLE_START - CDX-622 (TSLP SCF): Our first bispecific candidate for inflammatory diseases is CDX-622 which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin (TSLP) and depleting mast cells via stem cell factor (SCF) starvation. In November 2024, a Phase 1a dose-escalation study in healthy volunteers was initiated and enrollment is ongoing. ##TABLE_END

More detail on these programs is provided in the Clinical Development Programs section.

Our goal is to build a fully integrated, commercial-stage biopharmaceutical company

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CLDX_OUT_33 [2025-04-29 09:18:40 -0400] 1181 Bytes | 233 tokens | Cum: 6030 tkns (75.38% of 8k)
==========================================================================

Showing S1 (chunk 5 of 6): that develops important therapies for patients with unmet medical needs. We believe our program assets provide us with the strategic options to either retain full economic rights to our innovative therapies or seek favorable economic terms through advantageous commercial partnerships. This approach allows us to maximize the overall value of our technology and product portfolio while best ensuring the expeditious development of each individual product.

The expenditures that will be necessary to execute our business plan are subject to numerous uncertainties. Completion of clinical trials may take several years or more, and the length of time generally varies substantially according to the type, complexity, novelty and intended use of a drug candidate. It is not unusual for the clinical development of these types of drug candidates to each take five years or more, and total development co

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CLDX_OUT_35 [2025-04-29 09:18:42 -0400] 790 Bytes | 190 tokens | Cum: 6222 tkns (77.78% of 8k)
==========================================================================

Showing S1 (chunk 6 of 6): sts could exceed hundreds of millions of dollars for each drug candidate. We estimate that clinical trials of the type we generally conduct are typically completed over the following timelines:

##TABLE_START

Estimated

Completion

Clinical Phase

Period

Phase 1

1 2 Years

Phase 2

1 5 Years

Phase 3

1 5 Years

##TABLE_END

The duration and the cost of clinical trials may vary significantly over the life of a project as a result of differences arising during the clinical trial protocol, in...

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CLDX_OUT_37 [2025-04-29 09:18:49 -0400] 6041 Bytes | 1617 tokens | Cum: 7841 tkns (98.01% of 8k)
==========================================================================

This is our set of metrics for Celldex Therapeutics.
Please analyze the numbers.

+---------------------+-----------------------+-------------------------+------------------------+
| Volume: 999,719 | Perf Month: 6.91% | Option/Short: Yes / Yes | Sales Y/Y TTM: 1.99% |
+---------------------+-----------------------+-------------------------+------------------------+
| Avg Volume: 802.25K | Perf Quarter: -12.96% | Short Float: 13.57% | ROE: -26.84% |
+---------------------+-----------------------+-------------------------+------------------------+
| Rel Volume: 1.25 | Index: RUT | Short Ratio: 10.94 | ROI: -21.07% |
+---------------------+-----------------------+-------------------------+------------------------+
| RSI (14): 65.37 | Market Cap: 1.42B | Short Interest: 8.78M | Sales Surprise: 14.70% |
+---------------------+-----------------------+-------------------------+------------------------+
| ATR (14): 1.17 | Shs Outstand: 66.37M | Beta: 1.38 | EPS Surprise: 3.72% |
+---------------------+-----------------------+-------------------------+------------------------+
| SMA20: 20.04% | Shs Float: 64.70M | Sales Q/Q: -71.56% | P/E: - |
+---------------------+-----------------------+-------------------------+------------------------+
| SMA50: 9.29% | Inst Own: 114.58% | Sales past 5Y: 43.00% | Earnings: Feb 27 AMC |
+---------------------+-----------------------+-------------------------+------------------------+
| SMA200: -23.69% | Insider Own: 2.53% | Employees: 186 | |
+---------------------+-----------------------+-------------------------+------------------------+
| Perf Week: 12.78% | Insider Trans: 0.69% | Debt/Eq: 0.01 | |
+---------------------+-----------------------+-------------------------+------------------------+

The next section covers any insider trading by Celldex Therapeutics officers or majority shareholders (if available).

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 7020000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -157863000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 21.36
Average Volume: 871791.15
30-Day High: 21.36
30-Day Low: 15.13

[Detailed Financials: TTM 2024]
- Total Assets: $792,340,000.00
- Total Liabilities: $45,335,000.00
- Total Equity: $747,005,000.00
- Current Assets: $747,159,000.00
- Current Liabilities: $39,501,000.00

[Income Statement: TTM 2024]
- Revenue: $7,020,000.00
- Net Income: $-157,863,000.00
- Gross Profit: $6,820,000.00
- Operating Income: $-195,078,000.00
- Earnings Per Share (EPS): -2.45

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $-6,458,000.00

[Detailed Financials: FY 2024]
- Total Assets: $792,340,000.00
- Total Liabilities: $45,335,000.00
- Total Equity: $747,005,000.00
- Current Assets: $747,159,000.00
- Current Liabilities: $39,501,000.00

[Income Statement: FY 2024]
- Revenue: $7,020,000.00
- Net Income: $-157,863,000.00
- Gross Profit: $6,820,000.00
- Operating Income: $-195,078,000.00
- Earnings Per Share (EPS): -2.45

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $-6,458,000.00
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of Celldex Therapeutics (CLDX).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Celldex Therapeutics.

2) MARKET_SCORE[]
This conversation was initiated because CLDX is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for CLDX.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, CLDX could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect CLDX to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of Celldex Therapeutics.

11) ETHICAL_RATING[]
Rate Celldex Therapeutics’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of Celldex Therapeutics.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

CLDX_IN_39 [2025-04-29 09:18:50 -0400] 126 Bytes | 29 tokens | Cum: 8082 tkns (101.03% of 8k)
==========================================================================

====================================
[2025-04-29 09:18:50] # Analysis Completed
Elapsed Time: 26.23 seconds